Journal
ONCOTARGET
Volume 8, Issue 35, Pages 57938-57947Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.18488
Keywords
maternal embryonic leucine zipper kinase; molecular target; p21; p53; FoxO family
Categories
Funding
- OncoTherapy Science Inc.
- Grants-in-Aid for Scientific Research [26710007, 16H02676, 16KT0116] Funding Source: KAKEN
Ask authors/readers for more resources
MELK play critical roles in human carcinogenesis through activation of cell proliferation, inhibition of apoptosis and maintenance of stemness. Therefore, MELK is a promising therapeutic target for a wide range of cancers. Although p21 is a well-known p53-downstream gene, we found that treatment with a potent MELK inhibitor, OTS167, could induce p21 protein expression in cancer cell lines harboring loss-of-function TP53 mutations. We also confirmed that MELK knockdown by siRNA induced the p21 expression in p53-deficient cancer cell lines and caused the cell cycle arrest at G1 phase. Further analysis indicated that FOXO1 and FOXO3, two known transcriptional regulators of p21, were phosphorylated by MELK and thus be involved in the induction of p21 after MELK inhibition. Collectively, our herein findings suggest that MELK inhibition may be effective for human cancers even if TP53 is mutated.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available